糖尿病对COVID-19幸存者持续性影像学异常和肺弥散功能障碍的影响:一项为期3年的前瞻性队列研究
该前瞻性多中心队列研究纳入278例COVID-19幸存者,比较合并与不合并糖尿病者在出院后6个月、12个月、2年和3年时的肺部后遗症。3年随访时,糖尿病组呼吸道症状、影像学肺部异常和肺弥散功能障碍的发生率均高于对照组;糖尿病(OR 2.18)、过敏(OR 2.26)、女性(OR 2.70)、重型COVID-19(OR 4.10)和纤维化样CT改变(OR 5.64)是肺弥散功能障碍的独立预测因素。结论强调糖尿病对COVID-19幸存者影像学肺部异常和肺功能障碍的长期不良影响,为合并糖尿病的COVID-19康复者长期监测肺部异常提供了重要证据支持。
要点
- 3年随访时,糖尿病组COVID-19幸存者的影像学肺部异常发生率高于对照组。
- 糖尿病是肺弥散功能障碍的独立预测因素(OR 2.18,95% CI 1.04-4.59,p=0.034)。
- 纤维化样CT改变是肺弥散功能障碍的独立预测因素(OR 5.64,95% CI 2.28-13.98,p<0.001)。
核心结论
- 糖尿病对COVID-19幸存者的影像学肺部异常和肺功能障碍具有长期不良影响,为合并糖尿病的COVID-19康复者长期监测肺部异常提供了重要证据支持。
研究设计与样本
- 前瞻性多中心队列研究,纳入278例COVID-19幸存者(年龄63岁,IQR 57-69;女性103例,占37.0%),在出院后6个月、12个月、2年和3年进行系列胸部CT、症状问卷和肺功能检查,比较合并与不合并糖尿病者的肺部后遗症,并分析3年随访时肺功能障碍的独立预测因素。
关键影像表现/征象
- 3年随访时,糖尿病组呼吸道症状、影像学肺部异常和肺弥散功能障碍的发生率均高于对照组。
- 纤维化样CT改变是肺弥散功能障碍的独立预测因素(OR 5.64,95% CI 2.28-13.98,p<0.001)。
诊断标准与关键数值
- 糖尿病预测肺弥散功能障碍的OR为2.18(95% CI 1.04-4.59,p=0.034)。
- 过敏预测肺弥散功能障碍的OR为2.26(95% CI 1.09-4.74,p=0.029)。
- 女性预测肺弥散功能障碍的OR为2.70(95% CI 1.37-5.29,p=0.004)。
- 重型COVID-19预测肺弥散功能障碍的OR为4.10(95% CI 1.54-10.93,p=0.005)。
- 纤维化样CT改变预测肺弥散功能障碍的OR为5.64(95% CI 2.28-13.98,p<0.001)。
临床应用与阅片要点
- 对合并糖尿病的COVID-19幸存者进行长期随访时,应关注胸部CT上的持续性影像学肺部异常。
- 纤维化样CT改变与肺弥散功能障碍独立相关,阅片时需注意识别此类征象。
- 女性、有过敏史或重型COVID-19病史的幸存者出现肺弥散功能障碍的风险可能更高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Little is known about the long-term impact of diabetes on lung impairment in COVID-19 survivors over a three-year period. This study evaluated the long-term impact of diabetes on persistent radiological pulmonary abnormalities and lung function impairment in COVID-19 survivors over three years.
MATERIALS AND METHODS: In this prospective, multicenter, cohort study, pulmonary sequelae were compared between COVID-19 survivors with and without diabetes. Serial chest CT scans, symptom questionnaires and pulmonary function tests were obtained 6 months, 12 months, 2 years and 3 years post-discharge. The independent predictors for lung dysfunction at the 3-year follow-up were analyzed.
RESULTS: A total of 278 COVID-19 survivors (63 [IQR 57-69] year-old, female: 103 [37.0%]) were included. At the 3-year follow-up, individuals in the diabetes group had higher incidences of respiratory symptoms, radiological pulmonary abnormalities and pulmonary diffusion dysfunction than those in the control group. Diabetes (OR: 2.18, 95% CI: 1.04-4.59, p = 0.034), allergy (OR: 2.26, 95% CI: 1.09-4.74, p = 0.029), female (OR: 2.70, 95% CI: 1.37-5.29, p = 0.004), severe COVID-19 (OR: 4.10, 95% CI: 1.54-10.93, p = 0.005), and fibrotic-like CT changes (OR: 5.64, 95% CI: 2.28-13.98, p < 0.001) were independent predictors of pulmonary diffusion dysfunction in COVID-19 survivors.
CONCLUSION: These results highlight the long-term deleterious effect of diabetes status on radiological pulmonary abnormalities and pulmonary dysfunction in COVID-19 survivors. This study provides important evidence support for long-term monitoring of lung abnormalities in COVID-19 recovery survivors with diabetes.
引用
- Wu L, Han X, Chen L, et al. Impact of Diabetes on Persistent Radiological Abnormalities and Pulmonary Diffusion Dysfunction in COVID-19 Survivors: A 3-Year Prospective Cohort Study. Acad Radiol. 2024. PMID: 39069434. doi:10.1016/j.acra.2024.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。